anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Basal cell carcinoma (BCC) of the skin is the most common type of cancer that can be treated with various therapies including surgical removal. A number of factors can lead to the development of multiple BCC of the skin, including genetic disorders (e.g., nevoid basal cell carcinoma syndrome). Treatment of multiple BCC becomes much more challenging. In these trials, the experimental therapy: verteporfin PDT is compared to placebo PDT. PDT or photodynamic therapy in these studies is the combination of the photoactive drug verteporfin (given intravenously) and red light exposure of skin tumors.

The primary objective is to assess whether verteporfin PDT can completely eliminate multiple BCCs. Eligible subjects will have at least 3 BCCs. Study subjects won't know which treatment they have been been assigned to - this is done randomly (like flipping a coin). After study treatment, the BCCs in each subject will be closely observed and toward the end of the study all will be surgically removed and examined to verify response to study treatment. Safety will be assessed by testing blood samples before and after study treatment, and analyzing adverse events and skin reactions to the study treatment.
Methods of treating or preventing ophthalmic, otic, and nasal infections and attendant inflammation are described. The methods utilize ophthalmic, otic, and nasal compositions containing a new class of antibiotics (e.g. trovafloxacin). The compositions also contain one or more anti-inflammatory agents (e.g. dexamethasone). The compositions are utilized to treat ophthalmic, otic, and nasal conditions by topically applying the compositions to the affected tissues.
The present invention discloses a medicine special for treating femoral head necrosis and a preparing method of a medicine special for treating femoral head necrosis. The medicine is composed of an orally taken medicine and an externally applied medicine which are simultaneously in use, wherein the orally taken medicine is composed of scolopendras, radix dipsaci, achyranthes roots, rosewood, safflower, notopterygium roots, musk bones and yellow wine; the externally applied medicine is composed of more than twenty traditional Chinese medicines, such as long-noded pit vipers, notoginseng, hemlock parsley, frankincense, myrrh, Chinese polyphaga, radix dipsaci, etc. The orally taken medicine of the medicine special for treating femoral head necrosis has the advantages of reasonable component structure and precise compatibility. The orally taken medicine performs the actions of blood circulation activation, blood stasis dissipation, rheumatic pain expelling, pain relieving, kidney invigoration, marrow alternation, tendon continuation and bone generation. The orally taken medicine is an ideal orally taken Chinese patent medicine for treating the femoral head necrosis. The externally applied medicine of the medicine special for treating femoral head necrosis performs the actions of bone generation, tendon continuation, meridian and collateral clearing, rheumatic pain expelling, pain relieving, blood circulation activation and tissue regeneration promotion. The externally applied medicine is an ideal externally applied Chinese patent medicine for treating the femoral head necrosis. The present invention mainly has remarkable effect on the treatment of the femoral head necrosis, rheumatism, rheumatoid diseases and arthralgia.
Relapsed disease is the primary cause of treatment failure after hematopoietic cell transplant (HCT). In this study, patients are given increasing levels of tagraxofusp (Tag) to evaluate the safety of each dose. Participants will start treatment with Tag starting between 60 and 120 days following HCT. Tag will be given by IV over about 15 minutes on days 1 through 3 of cycles 1-4 of treatment (28 day cycles) and then on days 1 and 2 of subsequent cycles, for up to 9 cycles or until disease progression or if you have a bad side effect. In the first cycle, Tag will be given while participants are inpatient. In all other cycles, Tag will be given outpatient and participants will be observed for 4 hours following each infusion. After about 4 cycles of treatment and again about 1 year after HCT, participants will have a bone marrow biopsy and also take a questionnaire about their quality of life. During the study, participants will have their blood checked regularly to monitor for side effects.
Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
Obesity is a major public health problem worldwide. Different approaches are known to face this problem, for example, dieting, surgery, or drug interventions. It has also been shown that placebos may help to reduce weight and hunger feelings, but the use of placebos is linked to problems with respect to the patient-healthcare-provider relationship. However, recent studies demonstrated that even placebos without deception (open-label placebos) affect symptoms such as pain, anxiety, or emotional distress. Here we aimed to examine whether an open-label placebo may help to lose weight in obesity. Our study included fifty-seven overweight and obese patients who aimed to lose weight using a combination of diet and sports. Patients were randomly divided into two groups. Participants in the open-label placebo group received two placebos each day. A treatment-as-usual group received no pills. Primary outcome included changes of body weight. Secondary outcomes were change of eating behavior and self-management abilities. After 4 weeks we found that participants in the open-label placebo condition lost more weight than the treatment-as-usual group. Furthermore, OLP treatment affected eating behavior. No effects for self-management abilities were found. Although further research is necessary, open-label placebos might help individuals to lose weight.
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT. Therapy options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. One method of solving relapse is to intervene before hematologic or pathologic relapse occurs based on minimal residual disease (MRD) . DLI is an effective post-transplantation therapy based on MRD for relapse. Whether combination of hypomethylating agents (HMA) and DLI could improve outcomes remains unclear. In this prospective randomized controlled study, the safety and efficacy of HMA+DLI and DLI preemptive therapy based on minimal residual disease in acute leukemia undergoing allo-HSCT are evaluated.
The C-reactive protein/albumin ratio (CAR) has recently emerged as a marker for poor prognosis or mortality in various patient groups. This study aimed to examine the relationship between serum CAR and infarct-related artery (IRA) patency in 700 consecutive non-ST-segment elevation myocardial infarction (NSTEMI) patients prior to percutaneous coronary intervention. The study population was separated into 2 different groups according to preprocedural IRA patency as assessed by the degree of Thrombolysis in Myocardial Infarction (TIMI) flow. As a result, occluded IRA was defined as TIMI grade 0-1, while patent IRA was defined as TIMI grade 2-3. High CAR (Odds Ratio: 3.153 (1.249-8.022); P < .001) was found to be an independent predictor of occluded IRA. Additionally, CAR was positively correlated with the SYNTAX score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio; CAR was negatively correlated with left ventricular ejection fraction. The highest cut-off value of CAR predicting occluded IRA was found to be .18 with 68.3% sensitivity and 67.9% specificity. The area under the curve for CAR was .744 (95% CI: .706-.781) after the receiver-operating characteristic curve assessment.
PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsion of high stability by using an oligomeric condensate from fatty acids, glycerol and dicarboxylic acid as well as a specific hydrophilic surfactant as an emulsifier. SOLUTION: Glycerol, a higher straight-chain fatty acid, an aliphatic dicarboxylic acid and a higher branched-chain fatty acid are mixed and esterified to form an oligomeric condensate from glycerol, fatty acids and a dicarboxylic acid. This oligomeric condensate is used together with a hydrophilic surfactant to give the objective oil-in-water emulsion. The hydrophilic surfactant is preferably one or more selected from nonionic surfactants with an HLB of >=10, N-acyl acidic amino acids or their salts. The formulation of a hydrophilic nonionic surfactant is preferably 0.1-20wt.%, particularly 1-10wt.% based on the whole composition and the formulation of the oligomeric condensate is preferably 1-50wt.% based on the whole composition. A cosmetic using this emulsion shows good spreadability on skin and gives freshened feeling after being flown off with water.
A composition containing critical proportions of 3 to 5 parts filler, 25 to 35 parts chewing gum base, gum chicle or SBR synthetic rubber, a minimum amount of emulsifier and from 40 to 62 parts of a water based emulsified phase. The emulsified water phase contains 3 to 6 parts sweetener and dissolved, inorganic mineral salts, such as sodium, potassium, calcium and magnesium chlorides and potassium phosphates, at a concentration of about 1% to 3% of the water phase, which is in the physiological range to ameliorate medical conditions such as xerostoma by controlling release of the dilute mineral salt solution during chewing thereof. When saliva is lacking, the liquid may contain dissolved salts higher than the physiological level, with or without 2 to 30 parts per million fluoride ions, so as to prevent demineralization of teeth. Under the direct supervision of a physician or dentist, the fluoride ions (NaF, SnF2 or sodium fluorophosphate) may be increased to 500 to 1000 parts per million depending upon frequency of use. Other additives may be introduced to the water phase such as coating compositions for the teeth or medicants released to the digestive system. It is essential that the composition be packaged in a moisture-proof seal which can be accomplished with a foil coated wrapping inside a moisture barrier plastic, glass or metal container.
Acute on Chronic Liver Failure (ACLF) is an unfavorable form of cirrhotic disease progression, distinguished from decompensated cirrhosis by a very high short-term mortality associated with damage to one or more organs. The pathophysiology is based on an intense systemic inflammatory reaction, the triggering factor of which can be identified (infection, toxic agent, etc.) in around two thirds of cases. The analogy with sepsis has enabled us to derive prognostic scores linked to organ damage, and thus to better guide these patients, who most often require close monitoring. Treatment remains limited and relies on support for the affected organs. Given the poor prognosis of these patients, attitude discussions should also be part of early management.
In recent decades, unhealthy dietary patterns and insufficiency of physical activity have brought negative effects on human health, such as rapid increasing incidence of obesity, metabolic cardiovascular diseases, and mental disorders. The first line of prevention and therapy for these diseases is proper diet and lifestyle interventions. A series of studies conducted in vivo and vitro have shown that high-fiber diets and time-restricted eating present benefits in weight loss, reducing cardiovascular disease risk, and improving cognitive function. While, there is also a randomized controlled trial do not observe the effects of time-restricted eating on weight loss and decrease of metabolic risks. Meanwhile, few studies have examined the effects of high-fiber diets or time-restricted eating on executive function. Additionally, previous studies on high-fiber diets and time-restricted eating focused on middle-aged or elderly populations with some features of metabolic syndrome, while the effects on healthy young populations are unclear. More importantly, there are a small amount of studies exploring the combined effects of time-restricted eating and physical activity on metabolism and cognitive function. Therefore, our study is to estimate the effects of diet (high-fiber diets and time-restricted eating) and exercise (rope-skipping) interventions on body weight, cardiovascular metabolic markers, executive function, and intestinal flora among undergraduate students, as well as the underlying mechanisms.
Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with pomalidomide 4 mg, capsules, orally from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of pomalidomide or dexamethasone can start at that dose level in the study.
PURPOSE:To obtain a polylysine derivative having reduced action of cytotoxic substance on cell, by acylating a free amino group of a polylysine bonded to a cytotoxic substance and having a monoclonal antibody bond. CONSTITUTION:A free amino group of a polylysine which is bonded to a cytotoxic substance (e.g. antitumor component or diphtheria toxin) or an imaging component (e.g. <125>I or <119>Te), a monoclonal antibody bond is introduced into and has >=5, preferably about 8-50 polymerization degree is acylated (0.5-2.0 equivalent based on free amino acid of acylating agent is used) to give a polylysine derivative containing a hindered amino group. The bond ratio of the polylysine based on the total amino group is preferably 25-80% cytotoxic substance and 4-40% bond. The monoclonal antibody bonded to the polylysine derivative has improved cell selectivity.
Both tolerance and physical dependence can develop during use of opioid therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). 

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. 

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Buprenorphine hydrochloride should not be abruptly discontinued in a physically-dependent patient [see DOSAGE AND ADMINISTRATION]. If buprenorphine hydrochloride is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur, typically characterized by restlessness, lacrimation, rhinorrhea, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

Infants born to mothers physically-dependent on opioids will also be physically-dependent and may exhibit respiratory difficulties and withdrawal signs [see Pregnancy].
Purpose Of exploring the biomechanical effect of knee extension constraint rehabilitation on rehabilitation after anterior cruciate ligament (ACL) reconstruction. Methods: Recruit 60 patients after ACL reconstruction. Divide them into three groups by random block method: Knee extension constraint rehabilitation group (wearing a brace with limitation of knee extension), Placebo group (wearing a brace without limitation of knee extension), and Control group (no brace is worn). The three groups of patients received the same rehabilitation training from 1 to 12 weeks after surgery, starting from week 13 and intervening on the first day of each week (wearing braces). Five tests were performed at the end of the 12th, 24th, 36th, and 48th weeks after surgery. Vicon system and force platform system will be synchronized used to test walking, jogging, side-cutting, and jumping; The Isokinetic dynamometer system will be used to test muscle strength. Outcome evaluation indicators and statistical methods: (1) Mixed design two-way analysis of variances will be used for the following indicators: approach run velocity and jump height; knee flexion angle at initial foot contact with the ground; knee extension moment at the time of peak impact poster ground reaction force, study group will be considered as an independent variable while testing time as the variable for repeated measurements. (2) The knee flexion, valgus-varus, and internal-external rotation angles, and extension, valgus-varus, and internal-external rotation moments of each leg during support phase of each movement will be expressed as functions of normalized movement time and leg (involved or uninvolved) using regression analysis with dummy variable. A dummy variable will be used to represent involved and uninvolved legs. A forward elimination procedure will be used to determine the best regression equations. The regression procedure will be stopped when the contributions of powers of n+1 and n+2 have no significant contribution to the overall regression. The contribution of the dummy variable in the regression will be an indication of asymmetry of the movements of involved and uninvolved legs. The effect of study group on movement asymmetry will be determined by comparing the contribution of dummy variables to the overall regression among study groups using a one-way ANOVA. The effects of study group and testing time on the ACL injury risk index will be determined for each knee in each movement using two-way ANOVA with mixed model. Study group will be considered as an independent variable while testing time as a repeated measure variable.
1441108 Cross-linked polymers; photopolymerizing unsaturated polyurethane derivatives C A REDFARN 22 April 1974 [23 Jan 1973 3329/73 Headings C3R and C3P [Also in Division G2] Cross-linked polymers are prepared by first reacting a saturated linear polyether based polyurethane prepolymer with at least the stoichiometric amount of an ethenoid monomer which is a hydroxy-alkyl ester of acrylic acid or methacrylic acid, or with less than the stoichiometric amount of the ester and with a sufficient amount only of a saturated aliphatic alcohol containing at least 6 carbon atoms to make up the stoichiometric balance, and thereafter curing the resultant polymer by reaction with an ethenoid monomer selected from acrylic acid, methacrylic acid, alkyl and hydroxy alkyl esters of acrylic acid or methacrylic acid, styrene and divinyl benzene by exposure to u.v. light in the presence of a photo-chemical sensitizer. The ethenoid monomer used for curing may be added to the polymer after completion of the first reaction or may be present during the first reaction in which case it may be constituted by excess over the stoichiometric amount of the ethenoid monomer used in the first reaction. In examples a polyetherbased polyurethane prepolymer is reacted in the first stage with hydroxy ethyl acrylate or hydroxy ethyl methacrylate and optionally ethyl hexanol and where further monomer is required in the curing step with methyl methacrylate or butyl methacrylate. The sensitizers may be benzoin, anthraquinone, benzophenone, benzil, diacetyl, diphenyl sulphide, tetramethylthiuram sulphide, uranyl nitrate, uranyl propionate, stannic chloride, stannous chloride and titanium chloride. Dentures and printing plates may be produced from the polymers.
PURPOSE: The aim of this systematic review was to investigate the effectiveness of physiotherapy interventions on chest mobility in obstructive lung diseases.
METHODS: Searches were performed in PEDro, Pubmed and Cochrane Central Register of Controlled Trials databases without language restrictions between 2010 and 25th December 2020. Randomized controlled trials (RCTs) investigating physiotherapy interventions on chest wall mobility were included. Two independent reviewers screened studies, extracted data, and assessed methodological quality of included studies. The assessment of risk of bias was conducted using the PEDro scale for RCTs. The articles were excluded if they have less than 5 out of 10 score.
RESULTS: Five studies included had good to excellent quality. A total of 139 patients were included in all RCTs. Intervention duration ranged from a single session to 12 weeks and the intervention schedules varied, consisting of 1-24 sessions, lasting 5-45 min per sessions. Three studies used respiratory muscle stretching and releasing techniques, one study combined respiratory muscle stretching with aerobic training, and one study planned diaphragmatic breathing. Four studies assessed chest wall mobility with optoelectronic plethysmography, whereas one study used measuring tape.
CONCLUSIONS: The result of this first systematic review that investigates the effects of physiotherapy interventions on chest wall mobility in obstructive lung diseases suggests that more and better quality RCTs with objective measurement tools are required.
INTRODUCTION: Heimler syndrome (HS) is a rare disorder that includes sensorineural hearing loss (SNHL), nail abnormalities, and enamel hypoplasia. Patients with this syndrome can also exhibit ocular manifestations. At present, only a few cases of HS have been reported, existing knowledge of this syndrome is limited, and many cases have been misdiagnosed or even missed. This is the first report of Heimler syndrome with blurred vision as the first complaint, which was diagnosed by genetic analysis in the ophthalmology department.
CASE DESCRIPTION: An 8-year-old girl complained of bilateral visual blur and night blindness from birth. Ophthalmic examinations revealed bilateral retinitis pigmentosa with cystoid macular edema, visual impairment with hyperopia and astigmatism. Hearing test revealed bilateral severe sensorineural hearing loss. Dental examinations revealed enamel hypoplasia. In addition, whole-exome sequencing (WES) identified two pathogenic variants in PEX1: the previously reported missense variant c.2966T > C (p.I989 T), and the novel frameshift variant c.1671_1672del (p.G558Sfs*33).
CONCLUSION: Heimler syndrome is caused by compound heterozygous PEX1 pathogenic variants, c.2966T > C (p.I989 T) and c.1671_1672del (p.G558Sfs*33), which contributed to the diversity of clinical and genetic profiles in this patient. The main clinical manifestations include bilateral retinitis pigmentosa with cystoid macular edema, sensorineural hearing loss, and enamel hypoplasia. Systemic examinations are suggested for patients suspected of having pigmentary retinal dystrophy, especially combined with hearing-related impairments. Genetic testing can help us to make a definitive diagnosis.